Clinical Scorecard: NIH Analysis Links PFOA and PFOS to Increased Risk of ER-Negative Breast Cancer

At a Glance

Key Highlights

• Higher PFOA and PFOS concentrations were associated with increased ER-negative breast cancer incidence, but no clear association was observed with overall breast cancer risk.
• Compared with women in the lowest PFOA concentration group, those in the highest group had a 67% higher rate of ER-negative breast cancer; the corresponding difference for PFOS was 93%.
• These percentages describe relative differences between groups, not an individual woman’s probability of developing breast cancer.
• The analysis quantified 17 PFAS in blood samples collected before diagnosis and included a meta-analysis of previous research.
• The authors call for further research on populations with greater PFAS exposure and on newer PFAS replacement chemicals.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

• Higher blood concentrations of PFOA and PFOS were associated with increased ER-negative breast cancer incidence; the study did not establish causation.
• No clear association was observed between either chemical and overall breast cancer risk.
• The proposed non-hormonal mechanisms were not examined in this study.

Patient & Prescribing Data

The Sister Study enrolled 50,884 U.S. and Puerto Rico residents aged 35–74 who had no breast cancer diagnosis at enrollment and had a full or half-sister previously diagnosed with breast cancer. The PFAS analysis included 1,609 subsequent breast cancer cases and 2,269 comparison participants.

The article reports no treatment or prescribing recommendations. The authors state that PFAS exposure is potentially modifiable and that people can take measures to reduce exposure; they also call for further research.

Clinical Best Practices

• The study reports 67% and 93% higher rates between concentration groups; these are relative differences, not individual absolute risk.
• The study found an association with ER-negative breast cancer but no clear association with overall breast cancer risk.
• The authors proposed gene-activity or immune-system mechanisms, but these were not examined in the study.
• The authors call for further research on populations with greater PFAS exposure and on breast cancer risk associated with newer PFAS replacements.

Related Resources & Content

• Chang, Pullella, Keil, et al. Journal of Clinical Oncology. doi:10.1200/JCO-26-00318